Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Rhea-AI Summary

Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

The notice of meeting is available on Cellectis’ investor website.

Argus May 21 session

-3.83% close to close Open Argus

Details

News Market Reaction – CLLS

In the May 21 session, CLLS declined 3.83%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement schedules Cellectis’ annual general meeting for June 25, 2026 at 2:30 p.m. CET in ...

Analysis

This announcement schedules Cellectis’ annual general meeting for June 25, 2026 at 2:30 p.m. CET in Paris, a standard corporate-governance event rather than a new financial or clinical milestone. It follows recent updates on CAR‑T programs, financial results, and epigenetic editing research. Investors may focus more on upcoming clinical readouts and financial disclosures outlined in recent filings, while the effective F‑3 shelf and ongoing R&D spending frame the medium-term funding and execution backdrop.

Key Figures

AGM date: June 25, 2026 AGM time: 2:30 p.m. CET AGM venue street number: 11 rue Watt +2 more

AGM date

June 25, 2026

Scheduled annual general meeting

AGM time

2:30 p.m. CET

Scheduled annual general meeting start time

AGM venue street number

11 rue Watt

Biopark auditorium address in Paris

AGM venue floor

4th floor

Biopark auditorium floor location

Postal code

75013

Paris postal code for AGM venue

Historical Context

5 past events · Latest: May 12

5 events

1. May 12

   Clinical data update

   24h Move

   -0.5%

   Announced upcoming lasme‑cel and eti‑cel clinical data at EHA 2026.

2. May 11

   Quarterly earnings

   24h Move

   -0.5%

   Reported first quarter 2026 financial results to investors.

3. May 06

   Capital structure update

   24h Move

   -2.3%

   Published monthly statement of share capital and voting rights.

4. May 04

   Earnings date notice

   24h Move

   +1.6%

   Announced timing for release of Q1 2026 financial results.

5. Apr 27

   R&D platform update

   24h Move

   -0.3%

   Presented TALE-based epigenetic editing platform data at ASGCT meeting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gene-editing

1 terms

gene-editing medical

"a clinical-stage biotechnology company using its pioneering gene-editing platform"

Gene-editing is a set of laboratory techniques that change an organism’s DNA by adding, removing or altering specific genetic instructions—think of it as editing words in a document to fix a sentence. For investors, it matters because these tools can create new treatments, improve agricultural crops or reduce manufacturing costs, potentially driving product value, regulatory risk, research milestones and long-term revenue prospects for companies involved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

The notice of meeting is available on the Cellectis website: https://www.cellectis.com/en/investors/general-meetings/

About Cellectis     
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.     
    
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.  

For further information on Cellectis, please contact:         
     
Media contacts:              
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93      

Investor Relations contact:           
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

• Shareholder's meeting announcement PR_ENGLISH.pdf

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the 2026 annual general meeting of Cellectis (NASDAQ: CLLS)?

The 2026 annual general meeting of Cellectis is scheduled for June 25, 2026 at 2:30 p.m. CET. According to Cellectis, this shareholder meeting will address standard annual matters and is open to eligible shareholders under applicable procedures.

Where will Cellectis hold its June 25, 2026 annual general meeting?

Cellectis will hold its annual general meeting at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. According to Cellectis, shareholders should consult the official meeting notice for access details, participation conditions, and any required registration steps.

How can Cellectis (CLLS) shareholders access the 2026 AGM notice of meeting?

Cellectis shareholders can access the 2026 AGM notice of meeting on the Cellectis investor website. According to Cellectis, the online notice provides agenda details, proposed resolutions, and instructions for attending or voting at the June 25, 2026 annual general meeting.

What type of company is Cellectis (NASDAQ: CLLS) holding the 2026 AGM?

Cellectis is described as a clinical-stage biotechnology company developing cell and gene therapies with a gene-editing platform. According to Cellectis, the June 25, 2026 annual general meeting supports governance for its ongoing therapeutic development and corporate activities.